biostudies-literaturePatel SBNIAID NIH HHSNHLBI NIH HHS1-13https://www.ebi.ac.uk/biostudies/studies/S-EPMC12087282biostudies-literatureUnknown115Despite decades of research, standard therapies remain ineffective for most leukemias, pushing toward an essential unmet need for targeted drug screens. Moreover, preclinical drug testing is an important consideration for success of clinical trials without affecting non-transformed stem cells. Using the transgenic chronic myeloid leukemia (CML) mouse model, we determine that leukemic stem cells (LSCs) are transcriptionally heterogenous with a preexistent drug-insensitive signature. To test targeting of potentially important pathways, we establish ex vivo expanded LSCs that have long-term engraftment and give rise to multilineage hematopoiesis. Expanded LSCs share transcriptomic signatures with primary LSCs including enrichment in Wnt, JAK-STAT, MAPK, mTOR and transforming growth factor β sExperimental hematologyEx Vivo Expansion of Phenotypic and Transcriptomic Chronic Myeloid Leukemia Stem Cells.PMC12087282P30 AI027767R01 HL150078P01 HL131477Bassal MAWelner RSFranceski AMPatel SBKuznetsova VMatkins VRfalseEx Vivo Expansion of Phenotypic and Transcriptomic Chronic Myeloid Leukemia Stem Cells.Despite decades of research, standard therapies remain ineffective for most leukemias, pushing toward an essential unmet need for targeted drug screens. Moreover, preclinical drug testing is an important consideration for success of clinical trials without affecting non-transformed stem cells. Using the transgenic chronic myeloid leukemia (CML) mouse model, we determine that leukemic stem cells (LSCs) are transcriptionally heterogenous with a preexistent drug-insensitive signature. To test targeting of potentially important pathways, we establish ex vivo expanded LSCs that have long-term engraftment and give rise to multilineage hematopoiesis. Expanded LSCs share transcriptomic signatures with primary LSCs including enrichment in Wnt, JAK-STAT, MAPK, mTOR and transforming growth factor β s2022-01-01T00:00:00Z2022 Nov2026-06-01T05:16:44.027Z2026-04-08T09:31:00.009ZS-EPMC120872823611558010.1016/j.exphem.2022.09.001